Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials

DOI: 10.1007/pl00007092
World Journal of Urology, 2001, 19, 46-50.

#	Paper	IF	Citations
81	Influence of sildenafil on copulatory behaviour in sluggish or normal ejaculator male rats: a central dopamine mediated effect?. *Neuropharmacology*, **2002**, 42, 562-7	5.5	35
80	Neurologic, psychological, and aggressive disturbances with sildenafil. *Annals of Pharmacotherapy*, **2002**, 36, 1129-34	2.9	76
79	Modulatory activity of sildenafil on copulatory behaviour of both intact and castrated male rats. *Pharmacology Biochemistry and Behavior*, **2002**, 72, 717-22	3.9	23
78	The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. *Journal of Cerebral Blood Flow and Metabolism*, **2002**, 22, 1124-31	7.3	99
77	Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. *Journal of Neuroscience Research*, **2003**, 71, 485-95	4.4	57
76	Phosphodiesterase type 5 (PDE5) inhibitors. *Progress in Medicinal Chemistry*, **2003**, 41, 249-306	7.3	23
75	Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. *Brain*, **2003**, 126, 241-7	11.2	231
74	Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. *Cephalalgia*, **2004**, 24, 547-53	6.1	20
73	Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. *International Journal of Impotence Research*, **2004**, 16 Suppl 1, S34-7	2.3	62
72	Differential effect of the PDE5 inhibitors, sildenafil and zaprinast, in aging- and lipopolysaccharide-induced cognitive dysfunction in mice. *Drug Development Research*, **2004**, 63, 66-75	5.1	10
71	Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. *Drugs*, **2004**, 64, 13-26	12.1	58
70	Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. *Neurochemistry International*, **2004**, 45, 915-28	4.4	127
69	Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?. *International Journal of Impotence Research*, **2005**, 17, 383-4	2.3	21
68	Phosphodiesterases in the CNS: targets for drug development. *Nature Reviews Drug Discovery*, **2006**, 5, 660-70	64.1	308
67	Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. *Psychopharmacology*, **2006**, 183, 439-45	4.7	59
66	Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. **2006**, 110, 135-370		433
65	PDE5 inhibitors beyond erectile dysfunction. *International Journal of Impotence Research*, **2007**, 19, 533-43	2.3	57

64	Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. *Diabetes*, **2007**, 56, 1025-33	0.9	186
63	PDE inhibitors in psychiatry--future options for dementia, depression and schizophrenia?. *Drug Discovery Today*, **2007**, 12, 870-8	8.8	80
62	The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. *European Urology*, **2007**, 52, 1331-9	10.2	34
61	Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. *Psychopharmacology*, **2008**, 196, 643-8	4.7	94
60	High dosage sildenafil induces hearing impairment in mice. *Biological and Pharmaceutical Bulletin*, **2008**, 31, 1981-4	2.3	21
59	Role of phosphodiesterase 5 in synaptic plasticity and memory. *Neuropsychiatric Disease and Treatment*, **2008**, 4, 371-87	3.1	68
58	EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor. *Neurological Research*, **2009**, 31, 313-5	2.7	8
57	Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. *Psychopharmacology*, **2009**, 202, 419-43	4.7	219
56	A placebo-controlled study of sildenafil effects on cognition in schizophrenia. *Psychopharmacology*, **2009**, 202, 411-7	4.7	49
55	The effect of sildenafil citrate (Viagra) on cerebral blood flow in patients with cerebrovascular risk factors. *Acta Neurologica Scandinavica*, **2010**, 121, 370-6	3.8	18
54	Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression. *Behavioural Pharmacology*, **2010**, 21, 540-7	2.4	51
53	Current therapeutic targets for the treatment of Alzheimer's disease. *Expert Review of Neurotherapeutics*, **2010**, 10, 711-28	4.3	83
52	Sildenafil counteracts the inhibitory effect of social subordination on competitive aggression and sexual motivation in male mice. *Behavioural Brain Research*, **2011**, 216, 193-9	3.4	9
51	Sildenafil, a selective phosphodiesterase type 5 inhibitor, enhances memory reconsolidation of an inhibitory avoidance task in mice. *Behavioural Brain Research*, **2011**, 220, 319-24	3.4	35
50	The phosphodiesterase type-5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses apoptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups. *Neuroscience Letters*, **2011**, 488, 26-30	3.3	36
49	Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?. *International Journal of Impotence Research*, **2011**, 23, 17-23	2.3	16
48	Drug targets for cognitive enhancement in neuropsychiatric disorders. *Pharmacology Biochemistry and Behavior*, **2011**, 99, 130-45	3.9	107
47	Phosphodiesterases as therapeutic targets for Alzheimer's disease. *ACS Chemical Neuroscience*, **2012**, 3, 832-44	5.7	180

46	Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. *Neuropharmacology*, **2012**, 62, 1182-90	5.5	53
45	Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms. *Neurobiology of Learning and Memory*, **2012**, 97, 370-9	3.1	49
44	Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the activity of two atypical antidepressant drugs, mianserin and tianeptine, in the forced swim test in mice. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2012**, 38, 121-6	5.5	11
43	Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? a systematic review and meta-analysis. *Journal of Sexual Medicine*, **2012**, 9, 2404-16	1.1	40
42	The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans. *Psychopharmacology*, **2013**, 225, 303-12	4.7	11
41	Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2013**, 60, 285-94	6.8	73
40	PDE2 and PDE10, but not PDE5, inhibition affect basic auditory information processing in rats. *Behavioural Brain Research*, **2013**, 250, 251-6	3.4	8
39	Effects of lurasidone on executive function in common marmosets. *Behavioural Brain Research*, **2013**, 246, 125-31	3.4	15
38	The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral-electroencephalography study. *Journal of Psychopharmacology*, **2013**, 27, 600-8	4.6	21
37	Pharmacological Manipulation of Cyclic Nucleotide Phosphodiesterase Signaling for The Treatment of Neurological and Psychiatric Disorders In The Brain. **2014**, 77-114		1
36	Inhibition of Cyclic Nucleotide Phosphodiesterases to Regulate Memory. **2014**, 171-210		
35	Beyond Erectile Dysfunction: Understanding PDE5 Activity In The Central Nervous System. **2014**, 223-246		
34	PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. *International Journal of Cardiology*, **2014**, 172, 581-7	3.2	30
33	Phosphodiesterases and Cyclic Nucleotide Signaling In The CNS. **2014**, 1-46		2
32	Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. *Psychopharmacology*, **2015**, 232, 343-53	4.7	24
31	Protective effect of exercise and sildenafil on acute stress and cognitive function. *Physiology and Behavior*, **2015**, 151, 230-7	3.5	18
30	PDE and cognitive processing: beyond the memory domain. *Neurobiology of Learning and Memory*, **2015**, 119, 108-22	3.1	40
29	Sildenafil-related cerebral venous sinus thrombosis and papilledema: a case report of a rare entity. *Neurological Sciences*, **2017**, 38, 1727-1729	3.5	3

28	From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases. *Advances in Neurobiology*, **2017**, 17, 135-168	2.1	17
27	Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2017**, 26, 1033-1048	5.9	90
26	Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy. *Neurotherapeutics*, **2017**, 14, 182-190	6.4	8
25	Audiometry results and TEOAE and DPOAE amplitudes in men taking a phosphodiesterase type 5 inhibitor for erectile dysfunction. *Ear, Nose and Throat Journal*, **2017**, 96, E34-E39	1	2
24	Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations. *Neuroscience and Biobehavioral Reviews*, **2018**, 87, 233-254	9	36
23	The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review. *Journal of Cerebral Blood Flow and Metabolism*, **2018**, 38, 189-203	7.3	9
22	Effects of sildenafil and calcitonin gene-related peptide on brainstem glutamate levels: a pharmacological proton magnetic resonance spectroscopy study at 3.0 T. *Journal of Headache and Pain*, **2018**, 19, 44	8.8	7
21	Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. *Nature Reviews Drug Discovery*, **2019**, 18, 770-796	64.1	100
20	Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease. *Brain Research Bulletin*, **2019**, 153, 223-231	3.9	10
19	Tadalafil Treatment Improves Inflammation, Cognitive Function, And Mismatch Negativity Of Patients With Low Urinary Tract Symptoms And Erectile Dysfunction. *Scientific Reports*, **2019**, 9, 17119	4.9	11
18	Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist. *ACS Chemical Neuroscience*, **2020**, 11, 1726-1739	5.7	12
17	Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. *Biochemical Pharmacology*, **2020**, 176, 113818	6	24
16	Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2021**, 104, 110032	5.5	4
15	Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders. *Molecular Psychiatry*, **2021**, 26, 4570-4582	15.1	13
14	Memory Enhancers for Alzheimer's Dementia: Focus on cGMP. *Pharmaceuticals*, **2021**, 14,	5.2	3
13	Pyrazole Scaffold Synthesis, Functionalization, and Applications in Alzheimer's Disease and Parkinson's Disease Treatment (2011-2020). *Molecules*, **2021**, 26,	4.8	13
12	Sildenafil Alleviates Murine Experimental Autoimmune Encephalomyelitis by Triggering Autophagy in the Spinal Cord. *Frontiers in Immunology*, **2021**, 12, 671511	8.4	0
11	Novel Therapies for Parkinsonian Syndromes-Recent Progress and Future Perspectives. *Frontiers in Molecular Neuroscience*, **2021**, 14, 720220	6.1	0

10	Sildenafil Misuse for its Psychoactive Properties? A Case Report. *Journal of Addiction Medicine*, **2021**, 15, 522-524	3.8	1
9	PDE5 inhibition improves object memory in standard housed rats but not in rats housed in an enriched environment: implications for memory models?. *PLoS ONE*, **2014**, 9, e111692	3.7	9
8	The Effect of Daily Low Dose Tadalafil on Cerebral Perfusion and Cognition in Patients with Erectile Dysfunction and Mild Cognitive Impairment. *Clinical Psychopharmacology and Neuroscience*, **2019**, 17, 432-437	3.4	8
7	Antipsychotic Drugs. **2008**, 577-594		1
6	The current approach to the central effects of sildenafil □ role of nitric oxide:cGMP pathway. *Annales Universitatis Mariae Curie-Sklodowska Sectio DDD Pharmacia*, **2008**, 21, 139-147		
5	Intracellular and extracelluar cyclic GMP in the brain and the hippocampus.. *Vitamins and Hormones*, **2022**, 118, 247-288	2.5	
4	The Role of Sildenafil in Treating Brain Injuries in Adults and Neonates. *Frontiers in Cellular Neuroscience*, **2022**, 16,	6.1	2
3	The Interplay between cGMP and Calcium Signaling in Alzheimer□s Disease. *International Journal of Molecular Sciences*, **2022**, 23, 7048	6.3	2
2	No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer□s disease and related dementia: results from the Drug Repurposing for Effective Alzheimer□s Medicines (DREAM) study.		1
1	Cerebral haemodynamic response to somatosensory stimulation in preterm lambs is enhanced following sildenafil and inhaled nitric oxide administration. 14,		0